The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy

On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in adult patients with metastatic colorectal carcinoma (mCRC) with the BRAFV600E mutation who had received prior systemic therapy. Encorafenib plus cetuximab was e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Trullas, A., Delgado, J., Koenig, J., Fuerstenau, U., Dedorath, J., Hausmann, S., Stock, T., Enzmann, H., Pignatti, F.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809377/
https://ncbi.nlm.nih.gov/pubmed/33422765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2020.100031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados